C
Carlos Cordon-Cardo
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 620
Citations - 91832
Carlos Cordon-Cardo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 144, co-authored 589 publications receiving 84862 citations. Previous affiliations of Carlos Cordon-Cardo include The Rogosin Institute & Erasmus University Rotterdam.
Papers
More filters
Patent
Assay for screening compounds that selectively decrease the number of cancer stem cells
TL;DR: In this article, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs) was proposed, which may be used as a high throughput screen.
Journal Article
Loss of avidin-binding activity in renal cell carcinoma
Joel Sheinfeld,Victor E. Reuter,Warren D. W. Heston,William R. Fair,Myron R. Melamed,Carlos Cordon-Cardo +5 more
Journal Article
Tumor-specific serum peptidome patterns.
Paul Tempst,Josep Villanueva,David R. Shaffer,Andrew J. Martorella,Mark E. Robson,Kevin Lawlor,John Philip,Martin Fleisher,Hans Lilja,Eric C. Holland,Richard J. Robbins,Carlos Cordon-Cardo,Howard I. Scher +12 more
TL;DR: An automated procedure for the simultaneous measurement of peptides in serum that utilizes magnetic, reversed-phase beads for analyte capture and a MALDI-TOF MS read-out is developed, which is more sensitive than surface capture on chips as spherical particles have larger combined surface areas, and therefore higher binding capacity, than small-diameter spots.
Book ChapterDOI
The Role of Microarray Technologies in Bladder Cancer Management
TL;DR: This chapter summarizes the targets and role of microarray technologies as discovery and validation platforms of targets and biomarkers for the clinical assessment of patients affected with bladder cancer.
Posted ContentDOI
The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses
Richard G. Pestell,Zhiping Li,Xuanmao Jiao,Asha M. Robertson,Gabriele Di Sante,Anthony W. Ashton,Agnese DiRocco,Min Wang,Jun Zhao,Sankar Addya,Chenguang Wang,Peter McCue,Andrew P. South,Carlos Cordon-Cardo,Runzhi Liu,Kishan Patel,Rasha M. Abdel Hamid,Jorim Parmar,James B. DuHadaway,S.K. Jones,Mathew C. Casimiro,Nikolaus Schultz,Andrew V. Kossenkov,Lai Yee Phoon,Hao Chen,Li Lan,Yung-Wei Sun,Kenneth A. Iczkowski,Hallgeir Rui +28 more
TL;DR: In this paper , the DACH1 gene was found to be associated with increased DNA damage in response to genotoxic stresses, and increased homology directed repair and resistance to PARP inhibitors and TGFβ kinase inhibitors.